Companies/US/MRK

MERCK & CO., INC.

Income flow

Annual
MRK 10-K Income StatementPeriod 2025-12-31Source 10-K
Pharmaceuticalsegment$58BAnimal Healthsegment$6BRevenue$65B+1% Y/YGross profit$49B-1% Y/YCost of revenue$16BOperating profit$21B+6% Y/YOperating expenses$28BNet profit$18B+7% Y/YTax$3BR&D & other$17BSG&A$11B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$64.5B
  • Pharmaceuticalsegment$58.1B90.2%
  • Animal Healthsegment$6.4B9.8%
By geography
By geography$93.5B
  • United States$36.5B39.0%
  • Non-US$28.5B30.5%
  • EMEA$14.6B15.6%
  • Latin America$3.4B3.6%
  • Asia Pacific$3.0B3.2%
  • Other countries$2.9B3.1%
  • JP$2.7B2.9%
  • CN$1.9B2.1%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).2.39%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.2.89%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).3.32PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.266.7%Shares outTotal shares currently outstanding (issued and not retired).2.47BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).2.46B
Dividend calendar
Ex-dividend
2026-09-15
Pay date
2026-10-07
Last cash
0.85 · 2026-09-15
Stock splits
  1. 1048:10002021-06-03

Valuation

Trailing PE 14.2 (2025-12-31)PE trend

Fiscal PE4

PeriodEPSClosePE
2025-12-317.28103.1314.2
2024-12-316.7493.9413.9
2022-12-315.7199.2117.4
2021-12-315.1466.3912.9

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.